Phio Pharmaceuticals Corp. (PHIO)

NASDAQ: PHIO · IEX Real-Time Price · USD
0.690
-0.012 (-1.72%)
Jul 1, 2022 12:07 PM EDT - Market open

Company Description

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.

It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT.

It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.

Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Logo
Country United States
Industry Biotechnology
Sector Health Care
Employees 12
CEO Gerrit Dispersyn

Contact Details

Address:
257 Simarano Dr Ste 101
Marlborough, Massachusetts 01752-3070
United States
Phone 508 767 3861
Website phiopharma.com

Stock Details

Ticker Symbol PHIO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001533040
CUSIP Number 71880W204
ISIN Number US71880W3034
Employer ID 45-3215903
SIC Code 2834

Key Executives

Name Position
Caitlin Kontulis Vice President of Finance and Administrative and Secretary

Latest SEC Filings

Date Type Title
May 12, 2022 8-K Current report
May 12, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
May 10, 2022 8-K Current report
May 2, 2022 8-K Current report
Apr 29, 2022 3 Initial statement of beneficial ownership of securities
Apr 29, 2022 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 22, 2022 8-K Current report
Mar 22, 2022 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 3, 2022 4 Statement of changes in beneficial ownership of securities
Mar 3, 2022 4 Statement of changes in beneficial ownership of securities